Archive for July 2022
Efforts at value-based care focus on patients’ needs
Original Source What is the value of a treatment? As of July, the U.S. government has given out close to 600 million doses of COVID-19 vaccines at prices that ranged between $15-$20 per dose, which means they spent $10-$12 billion on shots. Research shows that, as of March, the U.S. vaccination program saved 2 million lives and $900 billion in…
Read MoreFormer Detroit radio voice takes cystic fibrosis fight to Egypt
Original Source Laura Bonnell had a translator, because the parents in the room were mostly poor, and it’s typically the wealthy in Egypt who speak English. When the screen filled with a picture of her daughters, though — her strong, beautiful, living, 27- and 25-year-old babies — there was no need for words. The universal…
Read MorePrice Controls Would Devastate Drug Development, Patient Access, Says New Analysis
Original Source: https://vitaltransformation.com/2022/07/build-back-better-act-total-market-impact-of-price-controls-in-medicare-parts-d-and-b/ Build Back Better Act Total market impact of price controls in Medicare parts D and B The Executive Summary The Build Back Better Act (BBBA) is designed to allow the US Government to ‘negotiate’ pricing under a set framework of reductions based upon the amount of time a drug has spent on…
Read MoreCRO Announces Expanded Decentralized Clinical Trial Offerings
CANTON, MI (6/7/2022) – MMS Holdings, a data-focused Contract Research Organization (CRO), is pleased to announce a strategic partnership with Medidata, a Dassault Systems company, to provide clients a full range of solutions for clinical data management (CDM) and decentralized clinical trial (DCT) technologies, including Medidata’s unified platform and Rave EDC (Electronic Data Capture). The partnership…
Read MoreNovel PTSD Treatment Advances Towards FDA Approval
MMS Holdings (MMS), an award-winning, data-focused contract research organization (CRO), announced today that it has been selected by MAPS Public Benefit Corporation (MAPS PBC) as its contract research organization for the development of a New Drug Application (NDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD). This announcement comes on PTSD Awareness day as the confirmatory Phase…
Read MoreCRO partners with private equity firm to expand data-focused clinical research services
CANTON, Michigan – June 28, 2022 – MMS Holdings Inc. (“MMS” or the “Company”), a leading data-focused contract research organization (“CRO”), today announced that Lindsay Goldberg, a leading family and founder-focused private equity firm, has completed an investment in the Company alongside MMS Founder and CEO, Dr. Uma Sharma, who will maintain a significant ownership interest.…
Read MoreDaicel Arbor Biosciences Expands Leadership and Announces Ravindra Ramadhar as its new President
Ann Arbor, MI (July 1, 2022) – Daicel Arbor Biosciences, a division of Daicel Chiral Technologies, and leader in developing molecular biology research tools, is pleased to introduce Ravindra Ramadhar as its new President. Previously Mr. Ramadhar was Director, Strategy & Business Development within Thermo Fisher Scientific’s Genetics Science Division. Ramadhar brings a vast technical background to Daicel…
Read MoreNew Funding Opportunity from the NIH: Small Business Transition Grant For Early Career Scientists
The National Cancer Institute (NCI) recently released a new funding opportunity for biotech companies and university researchers! The new Small Business Transition Grant funds the translation of technology from university to small business, as well as the transition of early career researchers from academia to industry. This award uses the Small Business Technology Transfer (STTR)…
Read MoreRecent White House Proposals on Cancer Research Would be Counterproductive
Earlier this year, the Biden Administration aimed to reignite the Cancer Moonshot through its proposed federal budget and an objective to reduce cancer mortality by 50% over the next 25 years. The White House proposes to increase public funding for cancer research and at the same time control the price of cancer treatments. A University…
Read MorePODCAST: Accelerated Approval Study and Implications for Rare Disease Patients
This podcast discusses the results of Vital Transformation’s latest research study outlining the impact of proposed changes to the Accelerated Approval pathway, and what this would mean for patients with rare conditions. The study quantifies the impact of the Accelerated Approval pathway in bringing new therapies for unmet needs to market, and the vital role…
Read More